Form 4: Candel Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

Candel Therapeutics' Chief Medical Officer, William Garrett Nichols, sold 10,428 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, sold 10,428 shares of common stock on January 15, 2025.
• The sale was executed at a price of $7.225 per share.
• This transaction was not a discretionary sale but was required to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Mr. Nichols beneficially owns 79,320 shares of Candel Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies have mandatory sell-to-cover policies similar to Candel Therapeutics.

Stakeholder Impact

• The sale has a minor impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Candel Therapeutics, insider trading, stock sale, Form 4, William Garrett Nichols, restricted stock units, tax obligations, CADL